A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients FINE Trial

Creative Commons License

Akman Demir G., Turkoglu R., Saip S., YÜCEYAR A. N., EFENDİ H., TURAN Ö. F., ...More

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, vol.56, no.4, pp.253-257, 2019 (SCI-Expanded) identifier identifier identifier


Introduction: To assess satisfaction and quality of life in patients with relapsing-remitting multiple sclerosis (RRMS) who were receiving fingolimod (0.5 mg/day) for 12 months as a second-line treatment after switching from injectable agents.